CDIB is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma

Purpose: Tumor mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) have been well recognized as molecular determinants of immunotherapy responsiveness. In this study, we aimed to construct a TMB prognostic model and explore biomarkers that have predictive potential for prognosis and ther...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of general medicine 2022-04, Vol.15, p.3809
Hauptverfasser:	Li, Zhou, Feng, Yanqi, Li, Piao, Wang, Shennan, Liu, Xinyue, Xia, Shu
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Analysis Genes Genetic aspects Health aspects Immunohistochemistry Immunotherapy Medical research Medicine, Experimental Prognosis T cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!